Skip to Content
Morningstar

Curaleaf Holdings Inc CURA

Morningstar Rating
Unlock
Stock XTSE Rating as of
CAD 7.68 −0.02 (0.26%)
View Full Chart
As of Delayed Price Closed
Unlock our analysis with Morningstar Investor
Start Free Trial

Company Report

View Archive

Cannabis Shares Rally (Again) on Next Incremental Step to Federal Rescheduling

Kristoffer Inton

Shares of Canadian-licensed producers and US multistate operators rallied massively on news that the US Drug Enforcement Administration will proceed with rescheduling cannabis to Schedule III from Schedule I. Schedule I indicates it is considered to have a high potential for abuse and no medical value. In comparison, Schedule III drugs are considered less dangerous, with a lower potential for abuse and having some medical value. We view the April 30 news as the next step in a long process by the Biden administration to relax the current federal prohibition. We view the market reaction as a reflection of how much pressure these stocks have faced rather than any new development.

Read Full Report

Price vs Fair Value

View History
CURA is trading at a 56% discount.
Price
CAD 7.70
Fair Value
CAD 22.90
Uncertainty
Very High
1-Star Price
CAD 29.98
5-Star Price
CAD 7.81
Economic Moat
Fjvy
Capital Allocation
Kcpdglc

Bulls Say, Bears Say

Bulls

Unique among US multistate operators, Curaleaf's acquisitions into Europe and Canada allow it to serve the growing European market as legalization expands.

Bears

Sales growth for legal sellers like Curaleaf are challenged by the lack of taxes in the illicit market.

Show More
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CURA is a good fit for your portfolio.
Get 7 Days Free

News

View All

Trading Information

Previous Close Price
CAD 7.70
Day Range
CAD 7.50–7.86
52-Week Range
CAD 4.58–8.73
Bid/Ask
CAD 7.60 / CAD 7.72
Market Cap
CAD 5.66 Bil
Volume/Avg
370,563 / 513,856

Key Statistics

Price/Earnings (Normalized)
—
Price/Sales
3.07
Dividend Yield (Trailing)
—
Dividend Yield (Forward)
—
Total Yield
—

Company Profile

Curaleaf is headquartered in Wakefield, Massachusetts, and cultivates and sells medicinal and recreational cannabis in the US. The company has operations in 17 states. Its brands include Curaleaf, Select, and Grassroots. The company has made acquisitions that give it exposure to the growing European market, a unique feature among US multistate operators.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Stock Style Box
Small Core
Total Number of Employees
5,650
Website
https://www.curaleaf.com

Competitors

Valuation

View More
Metric
CURA
TLRY
GTII
Price/Earnings (Normalized)
 ——47.42
Price/Book Value
 4.050.481.90
Price/Sales
 3.072.023.04
Price/Cash Flow
 72.30—12.36
Price/Earnings
CURA
TLRY
GTII

Financial Strength

Metric
CURA
TLRY
GTII
Quick Ratio
 0.310.961.62
Current Ratio
 0.851.922.72
Interest Coverage
 −0.24−4.398.83
Quick Ratio
CURA
TLRY
GTII

Profitability

Metric
CURA
TLRY
GTII
Return on Assets (Normalized)
 −3.72%−1.42%3.06%
Return on Equity (Normalized)
 −10.45%−1.82%4.55%
Return on Invested Capital (Normalized)
 −2.20%−0.92%3.80%
Return on Assets
CURA
TLRY
GTII
See how this stock stacks up to its competitors with Morningstar Investor
Start Free Trial

Drug Manufacturers - Specialty & Generic Industry Comparables

Screen in Investor
Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
ZTS
Zoetis Inc Class ASprbxmllXst$76.2 Bil
MKKGY
Merck KGaA ADRMrntlhyzcxZvgdtp$70.9 Bil
HLN
Haleon PLC ADRChpsysdmHsgs$37.8 Bil
VTRS
Viatris IncXgcqywvtZshz$14.0 Bil
RDY
Dr Reddy's Laboratories Ltd ADRMskychmyGxz$12.7 Bil
CTLT
Catalent IncMcktrgzvPjmngvn$10.2 Bil
PRGO
Perrigo Co PLCDcbnqbqrhBsmx$4.4 Bil
CURLF
Curaleaf Holdings IncTwngrfbbQzxh$4.1 Bil
PBH
Prestige Consumer Healthcare IncMsnqhqcvkFcgdjxm$3.5 Bil
GTBIF
Green Thumb Industries IncDxmbvtlsybGvyq$3.1 Bil

Sponsor Center